BioXcel Therapeutics, Inc.

BTAI

NASDAQ

Healthcare

Biotechnology

New Haven, CT, US37 employeesbioxceltherapeutics.com

$1.18

-0.04(-3.69%)

Mkt Cap $29M

$1.18

$6.80

52-Week Range

At a Glance

AI-generated

Revenue breakdown: Single Reportable Segment (100%).

8-K

BioXcel Therapeutics announced FDA acceptance of its sNDA for IGALMI in the at-home treatment of agitation in bipolar disorder or schizophrenia, with a PDUFA target date of November 14, 2026.

$29M

Market Cap

$1M

Revenue

-$117M

Net Income

Employees37

Fundamentals

How The Business Makes Money

Revenue by Segment

Single Reportable Segment100%($4M)

Activity

What Changed Recently

Management Change

Feb 5, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 4

Financial Results

Mar 26, 2026

, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende

Material Agreement

Mar 10, 2026

. Entry into a Material Definitive Agreement. Registered Direct Offering and Warrant Amendment On March 10, 2026, BioXcel Therapeutics, Inc. (the “Company”) ent

Other Event

Mar 31, 2026

| Other Events. | |---|---| ** ** On April 1, 2026, BioXcel Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has accepted

Other Event

Feb 11, 2026

Other Events. On February 12, 2026, BioXcel Therapeutics, Inc. (the “Company”) announced the completion of an updated market opportunity assessment for IGALMI®

Peer Companies

Company	Price	Change	Market Cap	P/E
MAIAMAIA Biotechnology, Inc.	$1.34	-0.37%	$52M	—
ANVSAnnovis Bio, Inc.	$2.27	+7.31%	$45M	-2.1
PYPDPolyPid Ltd.	$4.38	-0.34%	$45M	-2.5
VERUVeru Inc.	$2.30	+1.32%	$37M	-2.4
GBIOGBIO	$5.34	+0.00%	$36M	—
MURAMURA	$2.04	+0.00%	$35M	—
CELUCelularity Inc.	$1.34	+2.29%	$32M	-0.4
EVAXEvaxion Biotech A/S	$3.74	-5.08%	$24M	-3.2

Analyst View

Company Profile

CIK0001720893

ISINUS09075P2048

CUSIP09075P204

Phone475 238 6837

Address555 Long Wharf Drive, New Haven, CT, 06511, US

SEC EDGAR